Autonomix Enters into Definitive Agreement to License Intellectual Property for FDA-Cleared Ablation Technology from RF Innovations, Inc.

Core Viewpoint - Autonomix Medical, Inc. has entered into a definitive agreement with RF Innovations to license the Apex 6 Radiofrequency Generator, which aligns with the specifications required for Autonomix's ablation system and supports its FDA regulatory pathway [1][2][3] Group 1: Transaction Details - The transaction involves 250,000 shares of common stock and grants Autonomix a perpetual non-exclusive worldwide and royalty-free license for the Apex 6 Generator intellectual property [2] - The deal is expected to close before the end of July 2024 [1] Group 2: Technology and Development - The Apex 6 Generator is an FDA-cleared ablation technology designed for pain management in the peripheral nervous system [1] - Autonomix plans to utilize this technology to enhance its therapeutic areas and drive value across its pipeline [2][3] - The company is initially focusing on developing technology to address pancreatic cancer-related pain, which currently lacks effective solutions [4][6] Group 3: Strategic Implications - The licensing agreement is seen as a significant advancement for Autonomix's technology platform and may simplify its regulatory strategy due to the existing FDA clearance of the Apex 6 Generator [3] - Autonomix aims to adapt the technology for its specific use case, which could accelerate its journey towards commercialization [3] Group 4: Company Overview - Autonomix Medical, Inc. is dedicated to advancing innovative technologies for diagnosing and treating diseases involving the nervous system [5] - The company's technology platform includes a catheter-based microchip sensing array that detects neural signals with approximately 3,000 times greater sensitivity than current technologies [5]